# Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer

> **NCT00193219** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 36 (actual)

## Conditions studied

- Colon Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Cetuximab
- **DRUG:** 5-fluorouracil
- **DRUG:** Leucovorin
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT00193219
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2008-06
- **Final completion:** 2010-07
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2022-01-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00193219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00193219, "Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00193219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*